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Abstract
Glioma is recognized to be a highly heterogeneous CNS malignancy, whose diverse cellular
composition and cellular interactions have not been well characterized. To gain new clinical-
and biological-insights into the genetically-bifurcated IDH1 mutant (mt) vs wildtype (wt)
forms of glioma, we integrated data from protein, genomic and MR imaging from 20 treat-
ment-naïve glioma cases and 16 recurrent GBM cases. Multiplexed immunofluorescence
(MxIF) was used to generate single cell data for 43 protein markers representing all cancer
hallmarks, Genomic sequencing (exome and RNA (normal and tumor) and magnetic reso-
nance imaging (MRI) quantitative features (protocols were T1-post, FLAIR and ADC) from
whole tumor, peritumoral edema and enhancing core vs equivalent normal region were also
collected from patients. Based on MxIF analysis, 85,767 cells (glioma cases) and 56,304
cells (GBM cases) were used to generate cell-level data for 24 biomarkers. K-means clus-
tering was used to generate 7 distinct groups of cells with divergent biomarker profiles and
deconvolution was used to assign RNA data into three classes. Spatial and molecular het-
erogeneity metrics were generated for the cell data. All features were compared between
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IDH mt and IDHwt patients and were finally combined to provide a holistic/integrated com-
parison. Protein expression by hallmark was generally lower in the IDHmt vs wt patients.
Molecular and spatial heterogeneity scores for angiogenesis and cell invasion also differed
between IDHmt and wt gliomas irrespective of prior treatment and tumor grade; these differ-
ences also persisted in the MR imaging features of peritumoral edema and contrast
enhancement volumes. A coherent picture of enhanced angiogenesis in IDHwt tumors was
derived from multiple platforms (genomic, proteomic and imaging) and scales from individ-
ual proteins to cell clusters and heterogeneity, as well as bulk tumor RNA and imaging fea-
tures. Longer overall survival for IDH1mt glioma patients may reflect mutation-driven
alterations in cellular, molecular, and spatial heterogeneity which manifest in discernable
radiological manifestations.
Introduction
Gliomas represent the most common type of malignant brain tumor, comprising 81% of
malignant brain and central nervous system (CNS) tumors and 27% of all brain and CNS
tumors in the United States[1]. While gliomas are relatively rare in the general population
with an average annual age-adjusted incidence of 6.2 per 100,000, these primary brain tumors
contribute significant morbidity and mortality, with glioblastoma carrying a 5-year survival
rate of less than 6% [1].
The landscape of our knowledge about molecular features required for accurate diagnosis
and prognosis for glioma patients has advanced greatly in the last decade [2–5]. Molecular sub-
classification highlights different genetic underpinnings of glioblastoma [6], which offer some
prognostic insight [7], likely attributable, in part, to gene expression patterns influencing vul-
nerability to radiation [8]. The World Health Organization (WHO) classifies gliomas into
defined categories based upon histologic and molecular features; gliomas are assigned into
four grades of increasing aggressiveness. Additionally, the methylation status of O6-methyl-
guanine-DNA methyltransferase (MGMT) has been implicated as a useful biomarker for con-
ferring tumor resistance to alkylating chemotherapies; methylation of the MGMT promoter
leads to transcriptional silencing of MGMT, which is associated with loss of MGMT expres-
sion and increased response to alkylating chemotherapies such as temozolomide (TMZ) [9].
Analysis of DNA methylation from gliomas identified a DNA methylation-based phenotype,
G-CIMP, which is characterized by global hypermethylation of CpG islands and is predictive
of increased survival; this G-CIMP phenotype is associated with isocitrate dehydrogenase
(IDH) mutation status [3, 4, 10].
IDH wild type (wt) in histologically defined low-grade gliomas is associated with poor clini-
cal prognosis that more resembles glioblastoma multiforme (GBM), which generally lack IDH
mutation (IDHmt) [3, 11]. Conversely, IDH mutations are observed in the majority of lower-
grade gliomas and are associated with better clinical outcomes. In low-grade gliomas with IDH
mutations, 1p/19q codeletion is further associated with oligodendrogliomas and better chemo-
therapeutic response [12]. The validation of some of these molecular biomarkers for diagnosis
and prognosis has prompted WHO to include molecular subclasses into their latest classifica-
tion schema for CNS tumors, including addition of MGMT methylation and IDH-mutant/
IDH-wildtype classifications for glioblastoma, as well as IDH-mutant and 1p/19q-codeleted
classifications for oligodendrogliomas and anaplastic oligodendrogliomas [13].
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Intratumoral heterogeneity, even across molecular subtypes, is now also appreciated as a
characteristic of glioma and glioblastoma [14] and has been shown to occur temporally [15],
spatially [16] [17], for oncogenic drivers [18], and through the stem cell lineage [19]. Heteroge-
neity features have been identified by radiologic imaging with quantitative features, including
distinguishing between IDH1mt vs wt gliomas [20]. While these and other studies have inter-
rogated glioma heterogeneity using bulk transcriptomics and single cell sequencing, medical
imaging has also provided valuable heterogeneity insights, albeit limited by resolution (e.g. 1
voxel, the volumetric unit, in a 1.5 T MRI image contains approx. 1–2 million cells). There
have been no investigations to date of cell-level spatial heterogeneity in protein expression or
cell types and how they relate to the radiological appearance of these tumors on MRI. Under-
standing malignant progression in IDH1 mt and wt patients at multiple scales and in a spatial
context is pivotal to delineating biological events underlying glial tumors and may facilitate tai-
lored treatment approaches as well as reveal new therapeutic targets. Moreover, this multiscale
characterization may facilitate the identification of quantitative metrics derived from non-
invasive imaging, i.e. MRI, which correlate with or predict molecular and cellular phenotypes.
Such metrics may be evaluated for new patients prior to biopsy or surgery and might inform
about the presence of certain cellular characteristics that may affect treatment response or
outcome.
To discern multimodal differences in relation to IDHmt status, we conducted a multiscale
interrogative workflow which combines multiplexed immunofluorescence and single cell spa-
tial analysis of fixed glioma tissue, bulk genomic tumor sequencing, MR imaging quantitative
features of the whole tumor and subregions, and patient outcomes. Multiscale datasets were
assembled from treatment-naïve cases of grade 2, 3, and 4 astrocytoma/oligodendroglioma
(n = 20, referred as treatment-naïve glioma) as well as from recurrent (previously-treated)
grade 4 astrocytoma (glioblastoma) (n = 16, referred as recurrent GBM). Tumor tissue
punches from diagnostic paraffin blocks were assembled in duplicate (glioma) or triplicate
(recurrent GBM) into tissue microarrays for multiplex immunofluorescence staining [21]
using 43 markers to identify cell types and functional states corresponding to cancer hallmarks
[22]. Exome sequencing data were processed for mutations, copy number aberrations, as well
as insertions and deletions. Deconvolution of gene expression data from bulk tumor speci-
mens afforded comparisons of protein levels and transcript levels across cognate specimens.
An expert neuroradiologist (LW) outlined on MRI of the treatment naïve glioma, and of recur-
rent GBM (SJN), while advanced deep learning methods were utilized to delineate necrotic
and enhancing cores, as well as peritumororal edema. Morphologic features assessed the vol-
umes of the different regions and their ratios, while simple features, T1 weighted post contrast
(T1 Post), Apparent Diffusion Coefficient (ADC), and Fluid Attenuated Inversion Recovery
(FLAIR), were extracted from different MRI protocols.
Various MRI-focused studies [23–26] have investigated the ability of imaging features to
predict IDH1 mutational status. Studies focused on assessing the tumor volume, contrast
enhancement status [27], Visually AcceSAble Rembrandt Images (Vasari) feature set [28, 29],
radiomics features [30] or features that were derived via convolutional neural networks [31],
among others and used these to train predictive models of IDH1 mutational status. These stud-
ies showed great ability to predict IDH1 mutational status with accuracies as high as 89.1%
and area under the receiver operator curves (AUC) of 0.95. Other radiogenomic studies have
revealed the correlation of IDH1 mutational status with hypoxia induced angiogenesis and
identified that the relative cerebral blood volume (rCBV) MRI was able to predict IDH1 muta-
tions status with an 88% accuracy [32]. Unlike the latter studies that predict IDH1 mutational
status, we seek to reveal correlations between MRI derived quantitative features, cellular com-
position and spatial cellular heterogeneity to understand the mechanism of disease progression
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in relation to IDH1 mutational status. Such knowledge could enable creation of predictive
models on MRI of disease progression or treatment response without the need for an invasive
biopsy.
We show lower cell-level protein expression of most hallmark proteins included in this
study in IDH1mt vs wt cases consistent with lower aggressiveness of IDHmt tumors. Further,
IDH1mt gliomas, irrespective of grade, showed greater spatial heterogeneity but lower molecu-
lar heterogeneity of biomarkers associated with angiogenesis (VEGR2, CD31, SMA, S100A4)
and invasion (n-cadherin, cofilin, collagen IV, GFAP and vimentin). Similarly, cell classes
derived from deconvolution of bulk gene expression data showed the cell class with high
expression of most hallmark genes, particularly those belonging to enabling replicative immor-
tality, evading growth suppressors and inducing angiogenesis, were significantly under repre-
sented (<10%) in the IDHmt tumors. IDH mutation was co-expressed with ATRX mutations
and was mutually exclusive of EGFR and PTEN mutations consistent with known tumor biol-
ogy. Longer overall survival following diagnosis for IDH1mt glioma patients may reflect gener-
alized altered cellular, molecular and spatial heterogeneity, which is also reflected in the MR
images as lower enhancement and higher edema.
Materials and methods
Patient cohorts
Cohorts of 20 treatment-naïve gliomas (grades 2, 3, and 4 from the Ohio Brain Tumor Study)
and 16 post-treatment recurrent glioblastoma (grade 4 from University of California San Fran-
cisco [33]) were retrieved based on appropriate patient consent, availability of suitable MR
images, FFPE tissue, and specimens suitable for next-generation sequencing (Table 1 for sum-
mary data for the primary glioma and recurrent GBM patient cases and S1 and S2 Tables
for additional details on available sample types and imaging data). The Ohio Brain Tumor
Study was approved by the University Hospitals of Cleveland Institutional Review Board (UH
IRB# Case 1307-CC296). All participants provided written informed consent per the IRB
approved protocol: “My data and biological samples may be used for brain tumor genetic
research studies and/or genetic testing that may take place in the future as part of different
research studies”. And, “I agree that my anonymized information from this study may be put
into a National Institutes of Health publically available database”.
Workflow for multimodal data generation and integration
Using the methods provided below, three parallel analytical interrogations of the treatment-
naive glioma and recurrent cases were pursued: multiparametric MRI feature extraction; mul-
tiplexed immunofluorescence tissue imaging at single cell level; and RNA and DNA sequenc-
ing. Fig 1 depicts the overall workflow for this multimodal data generation, including multiple
analytical approaches to cluster and differentiate clinically variable phenotypes. Given the dif-
ferent clinical characteristics of the two cohorts and the multimodal nature of the data, our
analysis was stratified by cohort, yet we aimed at identifying patterns and associations that
were consistent across the two cohorts.
Multiplexed immunofluorescence imaging of disease and cellular
biomarkers
Using the original diagnostic FFPE tissue blocks of each case studied, dual (treatment-naïve
glioma) or triplicate punches (recurrent GBM) were selected for tissue microarray (TMA) con-
struction and subsequent multiplex immunofluorescence staining and imaging (MxIF). Two
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replicate TMA slides were used for the treatment-naïve glioma TMAs and 3 replicate TMAs
were used for the recurrent GBM TMAs. Control cores were included on all slides for glioma,
prostate, melanoma, lung, breast cancer (two per cancer type) to verify antibody performance.
Briefly, the Cell DIVE™ platform (GEHC, Issaquah WA) includes a protocol for antigen
retrieval, dye-conjugated antibody staining/inactivation (repeated n times), and imaging soft-
ware for up to 60 biomarkers in a single FFPE tissue section [21]. During the imaging work-
flow, the biomarker images are automatically processed for illumination correction, image
registration using the DAPI image (which is acquired in each round of imaging) and tissue
autofluorescence (AF) subtraction (AF is imaged on the unstained sample in each of the first 5
rounds and every fifth round thereafter). The processed images are then segmented into indi-
vidual cells and biomarker fluorescence intensity value is generated for every cell, along with
corresponding cell IDs and coordinates. Cell level data can be analyzed in a number of ways
including clustering and spatial analysis (S1A–S1C Fig). In the current study, TMAs were
stained in the above iterative process using 2–3 dye conjugated antibodies in each staining
round, for a total of 43 biomarkers. Selected biomarkers were associated with different cancer
hallmarks, cell lineage and cell segmentation [22]. Markers of iron metabolism were also
included as ferroptosis is an emerging field of study with mechanistic ties to glioma cell resis-
tance to therapy [34–36]. The detailed process for antibody validation (testing, conjugation,
antigen sensitivity and staining verification) is described in S2 Fig and described in supple-
mentary information of Gerdes et al [21]. Antibody clones, dye conjugate, staining concentra-
tion, staining round and hallmark assignments are provided in S3 Table.
Table 1. Patient characteristics.
Cohort Treatment naïve primary glioma
patients
Recurrent/Refractory GBM
patients
Patient number 20 16
Median (range) age at diagnosis
(years)
57 (26–77) 51 (29–66)
Gender
Male 12 12
Female 8 4
Ethnicity
Caucasian 18 15
Hispanic, Asian, African American 0,1,1 1,0,0
Histologic grade
II 5 -
III 7 -
IV 8 16
IDH1/2 mutation status
Mutant (IDH1 R132H) 8 3
Wildtype 12 13
1p19q codeletion
Codeletion 4 -
Non-codeletion 16 -
Median (range) Survival (days)
Grade II 1120 (420–2326) -
Grade III 487 (370–2964) -
Grade IV (GBM) 438 (222–541) 1031 (396–3771)
https://doi.org/10.1371/journal.pone.0219724.t001
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Staining quality assessment and cell segmentation
Staining quality of all multiplexed images was assessed by visual assessment of staining pat-
terns of individual markers in all samples and compared to controls and/or expected patterns.
Markers that failed to stain or had non-specific staining or very low or negative expression in
both cohorts were excluded from analysis. Since replicate slides were also available, staining
intensities were correlated between slides for both treatment-naïve glioma and recurrent GBM
cohorts (S3A & S3B Fig). Example stains for two different cores from one patient are shown
in (S3C Fig) and show striking consistency.
As described earlier, the single cell analysis workflow consists of cell segmentation and bio-
marker quantification steps (S1C Fig). First, image background was suppressed using top-hat
filtering followed by multi-level image thresholding. Second, nuclei were segmented using a
wavelet-based algorithm that uses both nuclei intensity and shape (blobness) information [37].
Nuclear segmentation was followed by whole-cell segmentation, where synthetic cell boundary
was extracted by applying Voronoi tessellation using the nuclei as seeds. To avoid producing
Fig 1. Overall workflow for generating multiscale, multiparametric data, extraction of various features and/or conversion to higher scales and analysis
approaches to differentiate phenotypes. Multiparametric MRI images (Panels A & B) were segmented for ROIs and various image features to characterize tumor and
subregions (necrosis, enhancing and edema) within the tumor. Multiplexed immunofluorescence tissue analysis (MxIF) (Panel C) provided (left-to-right) a virtual H&E
(vH&E), which is a pseudo-colored DAPI and AF image, and corresponding overlays of 46 markers (examples shown are for proliferation and angiogenesis markers).
Single cell data were generated for every multiplexed marker and intensities were binned into levels for each cell (low, medium or high using the 33rd and 67th quantiles
as the thresholds). The molecular “state” of each cell was computed using the ordinal level of each protein. For visualization purposes, the molecular “state” of a cell was
overlaid on the vH&E image (Panel D). Genomics data (Panel E & F), including IDH1 mutation status, were summarized into pathways, cancer hallmarks, and
enrichments for each tumor. Cell-level biomarker and MRI feature data were clustered across all glioma patients and by IDH 1 status (Panel G) and molecular and
spatial heterogeneity were analyzed relative to IDH1 mutation status or tumor grade (Panel H).
https://doi.org/10.1371/journal.pone.0219724.g001
Cell, tissue, and imaging differences in IDH1 mutant vs wild-type diffuse gliomas
PLOS ONE | https://doi.org/10.1371/journal.pone.0219724 December 27, 2019 6 / 27
very large cells from isolated nuclei, a constraint on the maximum distance between the
nucleus and the corresponding cell boundary was applied. Segmented images were visually
assessed for segmentation quality and compared with images of DAPI staining and virtual
H&E (generated from pseudo-color overlays of DAPI and tissue AF). One image (of 40 total)
in the glioma group failed to segment due to poor tissue quality. Five images (of 46 total) from
recurrent GBM group were removed from further analysis as the cores contained few (<10%)
tumor cells, or were cauterized.
Cell segmentation was followed by quantification of biomarker intensities in each cell. This
data, along with cell IDs and spatial coordinates, were saved as .csv files for statistical analysis
in R. Using the correlation of cell level DAPI signal from each staining/imaging round, a qual-
ity score was generated for every cell in each image, which ranges from 0–1 (0 being no regis-
tration, up to 1 for perfect registration). Only cells with quality score above 0.85 were included
in the statistical analysis. Scores below 0.5 are generally due to tissue shifting/movement and
loss. A summary of the minimum and maximum number of cells for each field of view (FOV)
is shown in S4A & S4B Fig. Excellent correlations were found for the number of cells in the
replicate slides for each cohort (>0.98). Slightly greater cell heterogeneity was found for one of
the recurrent GBM slides but slide to slide correlation was still high (0.74) S4C Fig.
Identification of cell clusters and biomarker co-expression
After exclusion of biomarkers which failed QC or staining criteria (as described above), unsu-
pervised cell clustering was performed with subcellular data from 24 biomarkers (subcellular
compartments used are indicated in S3A Fig). In total, 85,767 cells (from 20 treatment-naïve
glioma cases) and 56,304 cells (from 16 recurrent GBM cases) were used to cluster cellular data
for all biomarkers. Clustering was also conducted with smaller subsets of markers representing
individual hallmarks (e.g. angiogenesis, invasion and energetics). Log2-transformed median
cell intensity for each marker was used for K-means clustering. After trimming to reduce the
impact of extreme outliers at both 2.5% tails, median cell biomarker values were standardized
by the overall marker mean and standard deviation (since the distribution of marker intensity/
expression values varied significantly within and between marker type).
Cells were clustered into K groups based on the multi-dimensional marker space (equiva-
lent to number of markers used for clustering). The kmeans function provided by stat package
of R (v. 3.4.1) was used with K (= 2 to 15). We used 10 random starts (nstart = 10) to address
K-means clustering algorithm’s sensitivity to initial seeds. We also used multiple metrics to
determine the best number of clusters for the data such as Silhouette width, Calinsky criterion,
Sum of squares of errors, and consensus clustering metrics. For consensus clustering (R Con-
sensusClusterPlus package), a subset of 5,000 randomly selected cells (due to computational
constraints) were used. Consensus clustering iterates the clustering algorithm and examines if
each pair of samples consistently clusters together or not. K-means clustering with Euclidean
distance as metric was used for 1,000 iterations with 80% resampling. The cumulative distribu-
tion function (CDF) plot and the heatmap from consensus clustering were evaluated to guide
us to determine the best number of clusters, aided by other metrics mentioned above. For a
given K, each cell was assigned to one of the K clusters, and each tumor sample represented
according to the proportion of cells belonging to one of the K clusters. For the purpose of visu-
alization, lollipop plots were generated for each cluster and show the average protein profile of
each cluster compared to the population average. Lines to the left of the vertical axis show
lower than average expression, while to the right show higher than average expression. The
percentage of cells belonging to each cluster was also calculated and shown for each lollipop
plot.
Cell, tissue, and imaging differences in IDH1 mutant vs wild-type diffuse gliomas
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Exome and RNA Sequencing
Tumor and normal whole-exome sequencing and tumor RNA-sequencing data from the 20
treatment-naïve gliomas was studied; data was either produced from fresh-frozen tissue
(n = 16, 8 of which had been sequenced in The Cancer Genome Atlas) or from FFPE tissue
(n = 4) (S1 Table). Twelve of these were newly accessed for de novo analysis, and the remain-
ing data was already available. Pathology estimates suggested those 12 samples all had greater
than 70% tumor cell density and less than 50% necrosis. Data from sixteen post-treatment
recurrent fresh-frozen glioblastoma tumors previously sequenced as part of a clinical trial [33]
(data available in the database of Genotypes and Phenotypes (dbGaP) under accession number
phs001460.v1.p1) was also included (S2 Table). All 16 of these tumors had whole-exome
sequencing data, and fourteen had cognate RNA-sequencing data available.
Constitutional DNA from PBMCs was available for all 36 samples. For the eight fresh fro-
zen glioma samples, Qiagen AllPrep DNA/RNA Mini Kit (cat#80204) was used to isolate DNA
and RNA; for the four FFPE treatment-naïve glioma samples, Qiagen AllPrep DNA/RNA
FFPE Kit (cat# 80234) was used. Exome libraries were constructed from 200ng of DNA
(DIN = 3–5 for FFPE samples, DIN >8 for blood and fresh frozen samples) using KAPA Bio-
systems’ Hyper Prep Kit (cat#KK8504) and Agilent’s SureSelectXT V5 baits, containing cus-
tom content, following the manufacturer’s protocols. Custom bait content included copy
number probes distributed across the entire genome, along with additional probes targeting
tumor suppressor genes and genes involved in common cancer translocations to enable struc-
tural analysis. For high quality RNA (RIN>6.0, DV200>90%), RNA libraries were constructed
using Illumina’s TruSeq RNA Library Preparation Kit V2 (cat#RS-122-2001) with 500ng
inputs. For remaining RNAs (RIN<6, DV200>30%), libraries were prepared using Illumina’s
TruSeq RNA Access Library Prep Kit (cat#RS-301-2001) with either 40ng or 100ng inputs fol-
lowing the manufacturer’s protocol and sample quality/input recommendations. Libraries
were equimolarly pooled, quantitated, and sequenced by synthesis on the Illumina HiSeq 4000
for paired 82bp reads. FASTQ were aligned using bwa-mem (version 0.7.8) to the reference
genome from 1000 Genomes project build hs37d5 with decoy contigs [b37d5] and Ensembl
v74 for annotations. Somatic variants were called using lumosVar2 [38]. For this study, a
tumor-normal mode was used which the sample fraction of clonal variant groups is set to zero
in the constitutional sample.
Deconvolution of samples into cell classes from RNAseq data of bulk
samples
Multiple cell classes, characterized by different dominant biological processes, can be dis-
cerned by computational deconvolution of bulk gene expression data obtained from complex
samples [39, 40]. This approach is a practical alternative when available samples are not suit-
able or available for single-cell sequencing (scRNAseq). Deconvolution assumes that the ana-
lyzed sample is composed of a certain number of cell types or different cell states, called classes.
These classes do not necessarily fall into mutually-exclusive cell types. Instead, they represent
quantifiable components of the analyzed samples that exhibit distinct gene- or pathway-attrib-
utable behaviors. We employed the previously published CellDistinguisher algorithm to iden-
tify sets of genes that are expressed predominantly in one class relative to the others [41]. As
demonstrated in the Results, gene sets of ~50 genes led to robust assignments of cells into
three classes. These distinguisher gene sets were then used to derive class signatures and com-
pute sample compositions (fractions of cell types or classes in each sample) using the SSKL
(Semi-supervised NMF algorithm for KL divergence) algorithm from the CellMix package
[42]. To validate and support our findings with the multiplexed single cell data, we also
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explored how well cell type assignments based on gene expression data compared to those
based on protein expression measured by MxIF.
Calculation of molecular and spatial cell heterogeneity metrics
Molecular and spatial heterogeneity metrics were computed for the MxIF spatially resolved
cell data using a previously published heterogeneity analysis algorithm (MOHA) [43]. As
described in more detail below, this technique computes the molecular “state” of each cell in a
tissue section based on the fluorescence intensity of proteins within a given pathway, gene set
or cancer hallmark [22]. Spatial “states” is a summated score which depicts the degree to
which adjacent cells are of the same molecular state. The MOHA algorithm computes hetero-
geneity (or similarity or divergent states) metrics based on the distributions of these molecular
and spatially defined states.
The molecular state of a given cell was defined as an ordered set of the values for each individ-
ual marker. A complete list of the cancer hallmark gene sets and the markers that were assigned to
them is shown in S3 Table. The state of each marker was quantized into an ordinal value repre-
senting either a high, medium or low state, using the 33rd and 67th quantiles as the thresholds. The
specific ordering of the markers in a given gene set (i.e. concatenation sequence) is arbitrary but
was maintained consistently throughout the analysis. This process of computing the molecular
state was repeated for each cancer hallmark marker set and for each cell. Next, molecular hetero-
geneity metrics were computed as a normalized Shannon’s entropy of molecular states:
Molecular Heterogeneity ¼
 
PNm
i¼1 Pmi lnðPmiÞ
lnðNmÞ
The Pmi is the fraction of cells in molecular state i, and Nm is the number of possible
molecular states in the system. The number of possible states for a gene set was defined as
three raised to the power of the number of markers assigned to the gene set (e.g. 3^number of
markers). The molecular heterogeneity metric value can range from zero to unity (i.e. maxi-
mum heterogeneity). For each patient tissue sample, a molecular heterogeneity metric was
computed for each cancer hallmark.
Cell Spatial Heterogeneity is a summated score which depicts the degree to which adjacent
cells are of the same molecular state as that of an index cell, with each cell in the tissue section
serving as an index cell (example shown in S5 Fig). Identifying neighboring cells is necessary
for computing the spatial heterogeneity metrics. Two cells were classified as neighbors if the
Euclidean distance between the centers of the two cells was less than 1.3 times the sum of their
radii. The cell radii were computed from the segmented cell area after approximating the cell
as a circle. The spatial state metric was computed by surveying the neighbors of each cell and
counting only the number of neighbors in the same molecular state. This number of neighbors
represents the cell spatial state for each pathway or gene set. Having no neighbors in the same
molecular state is a valid cell spatial state. Therefore, the cell spatial state can range from zero
to the maximum number of neighbors a cell has. After going through every cell and their
neighbors, a frequency distribution was established for these cell spatial states. The cell spatial
heterogeneity was then computed as a normalized Shannon’s entropy of spatial states:
Cell Spatial Heterogeneity ¼
 
PZmax
k¼0 Psk lnðPskÞ
lnðZmax þ 1Þ
where, Psk is the probability of state k, and Zmax is the maximum number of neighbors a cell
can have as measured in the tissue sample. For each patient tissue sample, a spatial heterogene-
ity metric was computed for each cancer hallmark.
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MRI imaging protocols and image feature extraction
The multiparametric MRI (mpMRI) exams of the brain consisted of T2-weighted (T2), T1
weighted pre-contrast (T1 Pre), T1 weighted post contrast (T1 Post), Apparent Diffusion Coef-
ficient (ADC) derived from diffusion-weighted imaging (DWI), and Fluid Attenuated Inver-
sion Recovery (FLAIR) images. The subjects with recurrent GBM were imaged using 3 Tesla
GE scanners, while the treatment naïve subjects were imaged at a different institution using 3
Tesla Siemens scanners. Although the acquisitions were consistent in sequence types across
institutions, parameters such as relaxation and echo times were different, thus prompting sep-
arate image analysis for the two cohorts.
Tumor annotations on the MR images were manually outlined by an expert neuroradiolo-
gist to depict the extent of the whole tumor, including peritumoral regions, relative to the
FLAIR sequence. To the extent possible, an equivalent normal region on the contra-lateral side
of the brain was demarcated. A deep learning approach was trained on the Brain Tumor Seg-
mentation (BraTS) challenge data [44] and was utilized to divide the whole tumor segmenta-
tion into enhancing core and necrotic core based on T1-post contrast MRI. A U-net network
was trained using the T1 Post contrast MRI to identify the extent of the enhancing and
necrotic cores on the BraTS data. The training code and trained model are available (https://
github.com/mirabelarusu/deep_learning_inference_browser). The trained model was subse-
quently applied on the T1 post contrast MR images for the patients in our cohort to segment
the enhancing and necrotic cores. The peritumoral (edema) regions were obtained by subtract-
ing the enhancing and necrotic core from the whole tumor segmentation. Manual corrections
and automatic postprocessing were utilized when appropriate to improve the precision of the
annotations or remove minor disconnected regions. At the completion of these processing
steps, an annotation of the whole tumor, the peritumoral (edema) region, enhancing core, and
necrosis were obtained for each subject relative to the FLAIR protocol.
Pre-processing steps were applied on the mpMRI prior to feature extraction, including spa-
tial registration to align the FLAIR protocol relative to the others, in order to project the region
annotations on the rest of the protocols. Intensity normalization was applied in the entire
organ by using the normal regions as reference. Specifically, the intensities were normalized
such that the average intensity in the normal region had a value of 1. To perform this normali-
zation, we divided the intensity of each voxel by the average of intensities within the normal
region.
Image derived quantitative features were evaluated for each subject. Due to the limited
number of subjects in our study, the large number of protocols (n = 5) available for each sub-
ject and the multiple subregions available for each tumor (n = 4), we chose to consider only
three protocols (T1-post, FLAIR and ADC) and three tumor subregions (the whole tumor, the
peritumoral edema and enhancing core). We represented the tumor subregions by two image-
derived quantitative features (mean and standard deviation), resulting in 18 image-derived fea-
tures per subject. Also, for each subject, we included three morphologic features (the volume
of the enhancing core, the volume of the entire tumor and their ratio–which we refer to as the
normalized enhancing core volume).
Multimodality data integration and clustering
Finally, we investigated the associations between imaging quantitative features and other vari-
ables including cell cluster data, clinical parameters and cancer hallmarks based on cell protein
expression, RNA and DNA. Due to the different source and scales of the multimodal data
(clinical, MxIF, genomic, MRI), we discretized the most relevant features into “low”,
“medium” and “high” groups, based on the data ranges across the individual cohorts. Features
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were considered to be relevant for the multimodal association analysis either because they
were clinically utilized for decision making, e.g. IDH1 mutation status, age, and grade, or
because they showed consistent trends across both treatment naïve subjects as well as recurrent
GBM subjects. Based on the discretized variables, subjects were then clustered using hierarchi-
cal clustering with the Euclidean distance metrics.
Statistical analysis and data visualization
Using R software [45], individual biomarker expression differences between IDHmt and wt
patients were calculated using unpaired Student’s t-tests, and multivariate Random Forest clas-
sifier was used to classify IDHmt vs IDHwt patients using those features identified in the t-test,
with the performance of the classifier reported in both error (out-of-bag error rate) and AUC
(leave-one-out cross-validation). The proportions of cell clusters between IDHmt and wt
tumors were also compared using unpaired t-test. The p-values were not adjusted for multiple
testing.
R was also used to generate plots and figures for visualizing the molecular and spatial het-
erogeneity. The Mann-Whitney test was performed on all unpaired comparisons of molecular
and spatial heterogeneity metrics by condition with the computed p-value reported in each
plot. The p-values were not adjusted for multiple testing. The Pearson correlation coefficient
was computed and included on each of the slide to slide correlation plots.
We compared the MRI-derived features for patients that are IDHwt or IDHmt using
unpaired t-tests. False discovery rate was used to control for multiple comparisons. Similarly,
we compared the MRI-derived features within the binned RNA and protein expression levels
using unpaired t-tests across each bin pair within the three groups. Multiple comparison cor-
rection was applied within each MRI-variable evaluation (i.e. 3 comparisons per panel).
For survival analysis, Cox Proportional Hazard model was used for comparing IDHmt vs
wt patients, and Kaplan-Meyer curve was used to plot survival rates.
For the purposes of data visualization and interpretation, data was aligned by cluster, IDH1
mutation and patient ID. Biomarker intensities were grouped by cancer hallmarks (invasion;
energy metabolism; angiogenesis; stem cells; immune response; proliferation; resisting cell
death; DNA damage) and iron metabolism.
Results
Marker expression differences between IDH1 mt and wt tumors
Univariate and multivariate analysis of biomarker expression in the treatment-naïve glioma
cohort showed significantly lower values for vimentin (p = 0.0002), VEGFR2 (p = 0.0002), nes-
tin (p = 0.003), Ki67 (p = 0.006) and HLA1 (p = 0.008) proteins in IDHmt vs wt tumors (S6A
Fig). Three of these, VEGFR2, vimentin and HLA1 were also included in the multivariate
model using Random Forest which provided an AUC of 0.87 (error rate 5%) in predicting
IDH mutation status (S6B Fig). Since a majority of IDHmt tumors are derived from oligoden-
drogliomas which minimally express vimentin [46, 47] and IDHmt tumors are known to have
suppressed angiogenic pathways, differential expression of VEGFR2 and vimentin between
IDHmt and IDHwt is not surprising.
Cellular and genomic analysis shows cancer hallmark differences in IDH1
mt vs wt tumors
Cellular differences in IDHmt vs wt tumors. In total, 24 markers across 85,767 cells
from the 20 treatment-naive glioma cases underwent k-means clustering. Fig 2 shows
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unsupervised clustering and segregation of the cells into 7 clusters; marker intensity organized
by cluster, IDH1 mutation and cancer hallmarks (invasion; energy metabolism; angiogenesis;
stem cells; immune response; proliferation; resisting cell death; DNA damage) and iron metab-
olism. Relative biomarker intensities (compared to population mean) for each cluster are
shown in the lollipop plots in S7 Fig and were evaluated visually. Clusters 1 and 4 were com-
posed of cells from just two IDH1wt patient cases and had higher than average expression of
most proteins (and hence hallmarks) (Fig 2). Clusters 2 and 6 contained the largest numbers
of cells (21.0% and 21.9%, respectively, S7 Fig) from the greatest number of cases (12 and 11
cases, respectively, Fig 2). Cluster 2 was predominantly composed of cells from IDH1wt
tumors, while cluster 6 was predominantly composed of cells from IDHmt cases. Cluster 2 lol-
lipop plot shows lower expression of γH2AX, Sox2, SMA, and Ncad and higher expression of
FTL and FTH1, while remaining proteins were close to the population average. Cluster 6 had
lower expression of most proteins (S7 Fig), except pERK, CD31 and Ncad. Cluster 5 had aver-
age or lower than average expression of all proteins. Cluster 7 had average or above average
expression for most proteins. Both clusters were comprised of cells from both IDHwt and
IDHmt cases. Notably, visual inspection of the lollipop plots showed that both angiogenesis
and metabolism-related markers were generally lower in IDH1mt cases, as was expression of
antigen presenting machinery, i.e. HLA1, and invasion markers collagen IV and vimentin
(consistent with our earlier analysis). Interestingly, IDHwt cells had higher expression of ferri-
tin light and heavy chains, indicating increased iron storage in these cells. Removal of free iron
by enhanced iron storage has been implicated in evading ferroptosis by cancer cells. A more
Fig 2. Distribution and clustering of cells based on protein expression from all treatment-naïve patients. Unsupervised clustering of cell biomarker data revealed 7
distinct subsets (clusters) of cells. Cluster 2 is dominated by IDH1wt and Cluster 6 is dominated by IDH1mt cases. Clusters 1, 4 and 7 (which were less diverse patient
groups) show higher staining intensities of most markers (and cancer hallmarks) compared to Clusters 2, 5 and 6. Iron metabolism marker expression was generally
high in Cluster 2, but low in Cluster 6.
https://doi.org/10.1371/journal.pone.0219724.g002
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in-depth analysis of this pathway is necessary to determine if evasion of ferroptosis is indeed
driving the tumor growth in these patients. Fig 3 shows two representative examples of IDHwt
and mt tumor samples, with biomarker staining examples and lollipop plots for proteins in
clusters 2 and 6. IDHmt patients had significantly lower proportion of cluster 2 cells (Fig 3C;
p = 0.02) and higher proportion of cluster 6 cells (Fig 3F; p<0.0001 vs IDHwt patients). Over-
all, similar staining profiles and cluster patterns in IDHmt vs wt cases were found in the recur-
rent GBM cohort (data not shown).
Clustering of cells by angiogenesis, invasion and reprogramming cellular energetics hall-
mark proteins was also conducted. Confirming earlier results, IDHmt tumors had a signifi-
cantly higher proportion of cells with low expression of angiogenesis markers vs IDHwt
tumors (p<0.001). A summary heat map of angiogenesis clusters and IDHmt and wt patients
shown in S8 Fig. Otherwise, for the other hallmarks, IDHmt patients had higher proportion of
clusters with low invasion and energetic marker expression.
Cell cluster alignment with IDH and other glioma related mutations. Fig 4 shows cell
cluster distribution (A) aligned with IDH mutation status (B) and the other most common
mutations in treatment-naïve glioma patients. In concordance with known biology, IDH1
mutations were found to be mutually exclusive of EGFR and PTEN mutations (Fig 4B).
Fig 3. Biomarker images and lollipop plots for cluster 2 and cluster 6. Staining images for representative cases in Cluster 2 (A) and Cluster 6 (D), including a vH&E
image (top left), segmented image (top middle) showing individual cells, an image with cluster assignment to individual cells (top right) and a number of single marker
or multi-marker overlays representing expression of different hallmark proteins ((a): DNA breaks, gH2AX. (b): Iron metabolism; FTL, FTH1; (c): Cell Death, Cleaved
Caspase 3; (d): Proliferation, EGFR, pERK, Ki67; (e): Immune MHC1, PDL1; (f): Stemness, Nestin, SOX2; (g): Angiogenesis, VEGFR2, SMA, S100A4, CD31; (h)
Metabolism, FASN overlaid on DAPI (i) Metabolism, GSK3b, PKM2, CA9; (j) Invasion, GFAP, Collagen IV; (k) Vimentin, Cofilin & NCad.Panel B and Panel E show
the protein expression profiles of individual clusters (2 & 6, respectively); “lollipop” lines originate at the average expression of proteins in all cells measured from all
cases. Lines to the left of the average vertical axis show lower than average expression, while to the right show higher than average expression. Cluster 2 (Panel C) and
cluster 6 (Panel F) trend towards separating cases by IDH1 mutation status. Specifically, Cluster 6, which shows a lower than average expression of most hallmark
proteins, is significantly positively correlated to IDH1 mutation (Panel F); Cluster 2 cells with higher iron metabolism (FTL, FTH1) show a trend towards lower
representation in IDH1 mutant samples (Panel C).
https://doi.org/10.1371/journal.pone.0219724.g003
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IDH1mt samples appeared to be more homogenous, particularly those with concurrent ATRX
mutation, and were mostly dominated by the cluster 6 cell phenotype (based on earlier analysis
had lower than average expression of most markers). Approx. 50% of IDH1wt cases with
EGFR amplification had a high proportion of cluster 2 cells (overall, average biomarker expres-
sion, and lower DNA damage and stem cell markers, higher iron metabolism markers).
Fig 4. Cell cluster composition and Oncoprint of treatment naive gliomas. For each glioma case, Panel A portrays the fractional
distribution of its cells within each of the 7 clusters. Panel B depicts the genomic profile of each glioma case.
https://doi.org/10.1371/journal.pone.0219724.g004
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Cell cluster alignment with RNA expression and IDH status. The degree to which pro-
tein-based single cell clusters concur with deconvoluted, transcript-based cell class assign-
ments across treatment-naïve gliomas with IDHmt or wt was evaluated. Based on the gene
expression data of all measured genes, we identified three cell classes using CellDistinguisher,
each class having 50 or more distinguisher genes (S9 Fig). Exceeding three classes resulted in a
very short list of distinguisher genes for some classes, which diminishes the utility of compar-
ing states or functions across the classes. Class 2 and Class 3 were qualitatively similar to pro-
tein derived cell cluster 6 and Cluster 2, respectively (Fig 5). Ratios of the average staining
intensities for 21 markers in clusters 6 and 2 were calculated (Fig 5A). The ratios of the expres-
sion values for the same 21 genes were compared between RNA classes 2 and 3 (Fig 5B).
Fig 5. IDH1 mutation status drives cell phenotype at both the gene and the protein level. Ratios of the average staining intensities for 21 MxIF markers in clusters 6
and 2 were calculated (Panel A). Following deconvolution of the transcriptomes using CellDistinguisher, RNA expression counts (FPKM) for the mRNAs were used to
distinguish “class types” (n = 3) across the bulk sequenced specimens, then ratios of the expression values for the same 21 genes compared between Class 2 and Class 3
(Panel B). Fractional composition of each patient case by Cluster 2 or Cluster 6 (Panel C) or according to Class 2 or Class 3 (Panel D) was determined. Cases dominated
by cells belonging to protein cluster 2 were more likely to be found in IDH1 wild-type tumors, while cases for which cells from cluster 6 dominated were mostly IDH1
mutated tumors (Panel C). Similarly, the fractional composition of glioma cases comprised of gene expression class 3 were present in higher proportions in IDH1 wild
type samples, while class 2 cell types were more abundant in the IDH1 mutant ones (Panel D). The distinguisher genes of class 3 were enriched in genes related to cancer
hallmarks of “inducing angiogenesis”, “enabling replicative immortality” and “evading growth suppression” (see S4 Fig and S2 Table).
https://doi.org/10.1371/journal.pone.0219724.g005
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Fractional composition of IDHmt and wt cases within cell cluster 2 or 6 (Fig 5C) or within
RNA class 2 or 3 (Fig 5D) was determined. Consistent with earlier results, tumors dominated
by cluster 2 cells were more likely to be IDHwt, while cases with dominance of cluster 6 were
mostly IDH1mt. Similarly, the IDHwt tumors were mainly comprised of RNA class 3 markers
while class 2 was more abundant in the IDH1mt (Fig 5D). IDH1wt tumors were enriched in
class 3 cells (enriched in genes related to the cancer hallmarks of inducing angiogenesis,
enabling replicative immortality and evading growth suppression), while the IDH1mt samples
had a lower abundance of genes related to these cancer hallmarks.
Despite the differences in sample amount and preservation (fixed vs frozen), we have found
noteworthy similarity between the cell types and patient compositions identified from the pro-
tein biomarker intensities and the gene expression data. Except for FASN, GSK3b and NCad,
good directional correlation was observed in differential protein and gene expression between
cell clusters and RNA classes in the IDH1mt and IDHwt populations (Fig 5). Lack of concor-
dance between H2AX protein and transcript likely is due to staining intensity by anti-γH2AX
antibody reporting only the post-translationally phosphorylated form of the protein (instead of
total protein, which the transcript count would more reasonable reflect). It is unclear why there
was not good concordance for FASN, GSK3b and NCad, but directional discordance between
mRNA and protein for any given gene is not an unanticipated finding, and on an individual
gene level, is more discordant in tumor versus cognate normal tissue [48]. Underlying reasons
for this discordance include variant turnover rate of the protein versus mRNA, translational
efficiency due to ribosomal density and occupancy, RNA secondary structure, among others
[49]. However, the high concordant directionality of 17 of the 21 markers argues for robustness
of the biological inference that molecular features in cells from treatment-naïve gliomas are
related to IDH1 mutation status. We conclude that biomarker-based clusters 6 and 2 refer to
the same cells and/or processes as gene-expression-based classes 2 and 3. Although at individual
gene levels, mRNA and protein expression values don’t evince quantitative direct, strong corre-
lation, our findings indicate that looking at the behavior of cells at the gene set or pathway level
can lead to consistent patterns starting from different data types [49, 50].
Intratumor and spatial heterogeneity. In addition to the cell level protein expression
and cell composition within the IDHmt and wt tumors, we further investigated molecular and
spatial heterogeneity of the biomarkers in each of the hallmark categories. Examples of the het-
erogeneity metrics for the cell proliferation hallmark (comprising Ki67, nestin and EGFR) in
gliomas and recurrent GBMs are shown in Fig 6A, which shows the discretized (high (2),
medium (1), low (0)) expression values for each marker, and corresponding color-coding for
each cell. Heterogeneity calculated from the distribution of these states in different tumors
shows an inverse correlation between molecular and spatial heterogeneity in both treatment-
naïve glioma and recurrent GBM cohorts. IDHwt tumors had higher molecular heterogeneity
while IDHmt tumors were more spatially heterogeneous (S10 Fig). Similar trends were pres-
ent in both cohorts. Fig 6B shows a scatter plot of heterogeneity in the “inducing angiogenesis”
hallmark with the range of spatial and molecular heterogeneity metrics for gliomas and recur-
rent GBM samples, also encoded by IDHmt (red) and wt (blue) status. Trends in heterogeneity
of this hallmark were similar to those observed for the proliferation hallmarks, as well as acti-
vating invasion motility hallmark (S10 Fig). No other significant differences in heterogeneity
were found.
MR feature differences between IDH1 mutant and wildtype patients
Simple features derived from the MR images uncovered differences in discernable elements of
brain tumor dispersion from IDH1wt and IDH1mt patients. IDH1wt patients had larger
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enhancing cores (feature “Normalized enhancing core volume”), but less contrast uptake in
the peritumoral edema regions (feature “Edema T1 post”). On the other hand, the IDH1mt
patients lack a clearly defined enhancing core, but have increased contrast uptake on the T1
post contrast MRI protocol in the peritumoral edema region (Fig 7). These trends were
observed both in the treatment-naïve glioma as well as the recurrent GBM, and are not surpris-
ing since the IDH1mt are known to have less contrast enhancement than the IDH1wt [51].
Other intensity and volumetric features were evaluated on clinically important MRI proto-
cols, e.g. ADC or FLAIR, but they failed to show separation between IDH1 mutational status
or a consistent trend across the two cohorts. Thus, our analysis focuses on the normalized
enhancing core volume–measuring the enhancing core volume normalized to the entire
tumor volume, and the T1w MRI post contrast uptake in the peritumoral edema region. Statis-
tical significance was not achieved for any features after multiple comparison corrections likely
due to the small number of patients in each cohort.
Multimodal data association
Unlike previous studies [27],[28–31] that focused on predicting IDH1 mutational status using
MRI features, we assessed the correlations of MRI features with genomic and proteomic mark-
ers within the angiogenesis hallmark to characterize the differences between IDH1 mutational
Fig 6. Computed molecular and spatial heterogeneity metrics using the multi-omics heterogeneity analysis (MOHA) tool. The method first converts the
continuous marker intensity measures of each segmented cell into an ordinal value representing either a high, medium, or low state. Panel (a) presents an example for
the Sustaining Proliferative Signaling cancer hallmark. This gene set is composed of three markers: EGFR, Ki67, Nestin. The state of each of these markers can either be
high (2), medium (1), or low (0). Therefore, the three-marker gene set has 27 possible molecular states presented in the color-coded legend (far left). The scatter plot
(center) presents the spatial and molecular heterogeneity of treatment naïve gliomas and recurrent GBM samples. Images of tissues from four treatment naïve gliomas
(A-D) and four recurrent GBM (E-H) are presented with each segmented cell colored by their expressed molecular state. The spatial state distributions of these eight
samples are presented above the scatter plot. For the 4-gene set “inducing angiogenesis” (SMA [ACTA2], VEGFR2 [KDR], CD31 [PECAM1], and S100A4) hallmark,
IDH1 mutation status discriminates those cases with relatively lower molecular heterogeneity and relatively higher spatial heterogeneity in grade III treatment-naïve
glioma or recurrent glioblastoma. Mann-Whitney test p-values are presented for each nonpaired comparison. (panel b).
https://doi.org/10.1371/journal.pone.0219724.g006
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status. S11 Fig shows that larger enhancing cores are associated with higher RNA expression
levels in the “inducing angiogenesis” hallmark. A similar association is observed with the
expression levels of protein markers, i.e. S100A4 that is known to promote angiogenesis and
metastasis development [52], and VGFR2 that plays a fundamental role in neovascularization
[53]. These found associations were consistent regardless of the type of tumor, treatment naïve
glioma or recurrent GBM.
When investigating multimodal associations (Fig 8), we can also observe a consistent trend
across the two cohorts of patients. Not surprisingly, IDH1 mutations are found in lower grade
tumors, younger patients and have better overall survival. As also shown in Fig 7 and S11 Fig,
IDH1mt tumors have smaller enhancing cores but more contrast uptake in the edema regions
and show reduced expression levels of RNA and protein from the “inducing angiogenesis”
hallmark (Fig 8, highlighted box). Of the five angiogenesis hallmark cell clusters, cluster 4
(above average expression of VEGFR2, SMA and CD31) and cluster 5 (above average expres-
sion of VEGFR2 and S100A4), which are characterized by higher expression of angiogenesis
markers, show low cell percentages in the subjects with IDH1 mutations. On the other, the
IDH1wt tumors are molecularly more diverse and show more heterogeneous multimodal vari-
ables, yet still a general trend of higher expression levels of RNA and protein markers involved
in inducing angiogenesis and reduced overall survival. Clusters with average (cluster 3) and
lower than average expression (clusters 1 and 2) were distributed among all patients, however,
Fig 7. MRI-derived features appear to differentiate patients that carry an IDH1 mutation (IDH1mt) and those that are wild type (IDH1wt), regardless if subjects
are treatment naïve or have recurring GBM. T1w post contrast MRI for IDH1wt subjects (A,E), and IDH1mt (B,F). The white outlines show the extent of the tumor as
delineated by the expert neuroradiologist (LW). (C,G) Across the two cohorts, a similar trend may be notice when comparing the mean T1 post-contrast intensity signal
in the peritumoral edema region, suggesting an increase in enhancement in the IDH1mt in the peritumoral edema region when compared to the IDH1wt (C and G). An
opposite trend is observed when comparing the normalized enhancing core volume across IDH1wt and IDH1mt (D and H), indicating that IDHmt patients have
limited to no enhancement. None of these comparisons reach statistical significance after multiple comparison correction using false discovery rate.
https://doi.org/10.1371/journal.pone.0219724.g007
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relative proportion of these compared to the other two clusters was much higher in the IDHmt
patients. Age, grade and histology are confounding factors in the recurrent GBM progression
cohort as IDH1mt tumors tend to occur at younger age and are generally low grade oligoden-
drogliomas, however, as the similar trends were apparent in the recurrent cohort, which are all
grade IV GBMs, these observations probably reflect differences in biology between the
IDH1mt and IDH1wt tumors.
Discussion
We deployed a multiscale workflow which accommodates biomedical imaging (multi-parame-
ter MR imaging) of glial tumors, in situ multiplex immune detection of discrete biochemical
functional states in tissue sections from tumors at single cell level, and next generation
sequencing of DNA and RNA from those same tumors. The data produced by each technology
was post-processed to regions-of-interest and features (MRI), molecular state assignments of
individual cells in tissue (based on gene sets and signaling pathways interrogated by specific
antibodies), and molecular subtyping, pathway and hallmark mapping (determined by muta-
tions and cellular deconvolution from bulk RNA sequencing). A coherent picture of enhanced
angiogenesis in IDHwt tumors evident in non-invasive in vivo imaging features emerges from
the data derived from multiple platforms (genomic, proteomic and imaging) and scales from
individual proteins to cell clusters/states as well as bulk tumor. Results are consistent with
Fig 8. Comprehensive rendering of multiscale measurements in gliomas. Multiscale modalities depicted include: 1) clinical information (red), 2) IDH1 mutational
status (blue), 3) MRI derived variables (green), 4) RNA expression level of genes involved in the “inducing angiogenesis” hallmark (black), and 5) MxIF angiogenesis
markers or cell clusters (magenta). The data is binned in low, medium and high categories. Across the treatment-naïve gliomas (a) and the recurrent (post-treatment)
glioblastoma� (b) cohorts, it can be observed that IDHmt patients have low angiogenesis according to RNA expression levels and expression of S100A4 and VEGRF.
Those subjects also have high fraction of cells in clusters 1 and 2 (low angiogenesis markers), and low fraction of cells in cluster 4 and 5 (high angiogenesis markers (S8
Fig, cluster profiles of angiogenesis clusters). Moreover, MR Images for the same subjects have lower normalized enhancing cores volumes and measure higher
intensities on T1 post contrast. �Recurrent GBM (5 subjects are not shown since they were missing MxIF).
https://doi.org/10.1371/journal.pone.0219724.g008
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known observations at the molecular (suppression of proangiogenic markers in IDHmt
tumors) and imaging scales (no or low enhancement in IDHmt tumor), but now fill in the
gaps on how the two are linked through the intermediate scales of cellular states and their spa-
tial organization. Multiplexed immunofluorescence (MxIF) staining using 43 antibodies on
individual tissue sections (duplicate punches in a tissue microarray) afforded insight into the
clustering of single cell functional states from 20 treatment-naïve gliomas (grades 2–4) into 7
clusters. Discreet patterns of protein abundance across 7 hallmark phenotypes and 2 biochemi-
cal signature events (iron metabolism and DNA damage) suggest that broad segregation of
such functional states may be associated with IDH1 mutation status. Among the more robustly
discriminating hallmarks between IDH1 wildtype from IDH1mutant gliomas is that of angio-
genesis. The enhancement patterns, specifically how much of the tumor enhances (assessed by
the “normalized enhancing core volume” feature) and the contrast uptake in the peritumoral
edema region (Edema T1 post intensity), appear to be consistently correlated with the IDH1
mutational status, a trend that is conserved across the two independent cohorts we investi-
gated. Our findings suggest that the IDH1wt tumors have a more consistent enhancing pattern
with a clearly defined enhancing rim and little uptake elsewhere. On the other hand, the
IDH1mt tumors have a diffuse appearance on MRI without a well-defined enhancing rim and
with higher uptake in the edema region, on account of infiltrating cells. Previous studies have
linked poor survival with the peritumoral edema volume [54] and tumor volume [27]. More-
over, IDH1mt tumors are known to have less edema [51]. From the richness of the molecular
heterogeneity portrayed from MxIF scoring, comparing the functional states of adjacent cells
(whether they are similar or dissimilar) affords a calculation of spatial heterogeneity across the
different hallmark phenotypes. Here we find the unanticipated segregation of both treatment-
naïve gliomas as well as recurrent glioblastoma based on IDH1 mutation status within hall-
marks of “invasion motility”, “proliferative signaling”, and “inducing angiogenesis”. The geno-
mic profiling depicted what is already known about glial tumors, (the mutual exclusivity of
IDH1 mutations with EGFR and PTEN mutations, the co-existence of ATRX mutations only
within a subset of IDH1 low grade tumors, etc), but also revealed the heretofore unknown fre-
quent, diminished molecular heterogeneity of IDH1mt low grade tumors. Removal of free
iron by enhanced iron storage has been implicated in evading ferroptosis by cancer cells [34,
35]. Cluster 2, which was highly represented in IDH1wt tumors showed an increased expres-
sion of iron storage markers (FTL and FTH1) and decreased expression of γH2AX, a marker
of DNA breaks (S7 Fig). This is consistent with increased sequestration of iron, making it
unavailable for oxidative DNA damage leading to evasion of ferroptosis. A more in-depth
analysis of this pathway that includes iron transport, storage and utilization is necessary to
determine if evasion of ferroptosis is indeed driving the tumor growth in these patients [55,
56]. Inter- and intra- tumoral molecular heterogeneity is a well-recognized feature of GBM [6,
57, 58] and is believed to be the main reason behind treatment failure. Emergence of several
single cell analysis platforms has fueled the investigations of intra-tumoral heterogeneity of gli-
oma [17, 59–61], including tumor-stromal cell interactions [62, 63] as well as interactions
between the diverse tumor cell populations [64, 65]. Importance of the intercellular interac-
tions among heterogeneous tumor cell population is highlighted by the observations of Inda
et. al. [64] that EGFRmt cells that are far outnumbered by the EGFRwt population drive
enhanced proliferation of these cells by paracrine signaling thereby driving tumor growth.
Thus, tools to evaluate molecular and spatial heterogeneity and cell-cell interactions are likely
to unravel heretofore unknown mechanisms that drive tumor growth and/or treatment failure.
IDH mutation induced suppression of immune response has also been noted previously, how-
ever, it has been linked to decreased expression of effector T cell response related genes [66].
Whether this in turn affects the expression of HLA1 in IDHmt tumors is not known.
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Study limitations
The key limitations of this study include small sample size, lack of registration of sample
derived for molecular analysis to MR images and a limited number of markers representing
different hallmarks. The intent of this study was not to generate a diagnostic signature but to
evaluate correlation between imaging and molecular features at the hallmark level and to gen-
erate a workflow for integrating multiscale multiparametric data to study disease biology.
While the sample size (n = 20) in the treatment-naïve glioma cohort was limited, the fact that
similar cell clusters existed in another cohort (recurrent GBM) and the correlations between
MR and molecular features of angiogenesis hallmark hold for both cohorts is encouraging.
Having developed methods to integrate and evaluate such a complex data set, we are in the
process of designing a more focused study to interrogate the biology of a specific molecular
subtype of GBM that will consider and address the aforementioned shortcomings.
Supporting information
S1 Table. Detailed patient characteristics and datasets for treatment naïve glioma cohort.
(TIF)
S2 Table. Detailed patient characteristics and datasets for recurrent GBM cohort.
(TIF)
S3 Table. Antibody information and staining sequence.
(XLSX)
S4 Table. Min and max number of cells per core in glioma and recurrent GBM TMAs.
(TIF)
S1 Fig. Multiplexed immunofluorescence (MxIF) workflow. The Cell DIVE MxIF workflow
involves repeated cycles of staining, imaging and signal inactivation (panel A), following slide
clearing and antigen retrieval. Prior to antibody staining, tissue is stained with DAPI and
imaged in all channels of interest to record background autofluorescence (AF) of the tissue.
Following background imaging, tissue is stained with 2–3 antibodies and reimaged to capture
antigen-specific signal and then undergoes a dye inactivation step to remove the signal. The
slide is re-imaged to measure background fluorescence intensity. These cycles are repeated
multiple times until all targets of interest have been imaged. Panel 2 shows various image pro-
cessing steps prior to generating single cell data. Some of these are performed during imaging
itself while others are performed post image acquisition. The steps include, illumination cor-
rection, to correct for uneven illumination across the FOV, registration of images from all
rounds (using DAPI signal from each round) and tissue AF removal. Panel C: Staining inten-
sity of various cellular and subcellular markers is used to generate cellular segmentation
masks. Segmented images are compared with real or virtual H&Es (generated from DAPI
stained background images at the beginning of multiplexing) by a trained biologist or patholo-
gist, and images with poor segmentation are removed from analysis. In parallel, marker stain-
ing is evaluated by reviewing AF removed images and markers that failed to stain or images
with large artefacts are removed from analysis. Marker expression is quantified at cellular and
subcellular compartments and data is generated in an easy to use .csv or Excel format which is
then analyzed by a variety of different tools/approaches including simple statistical correla-
tions, cluster analysis as well as heterogeneity analysis.
(TIF)
S2 Fig. Antibody validation workflow. A typical antibody validation workflow: Starting with
literature reports to identify antibody clones previously used for IHC on FFPE tissue, 3 or
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more clones per target are identified and evaluated for sensitivity and specificity of the signal
on a multi-tissue array (TMA) comprising all major tumor types and corresponding normal
tissues. The down-selected antibody is conjugated with CY3, Cy5 or Cy7 at 2 different dye/
protein ratio and conjugates validated by staining comparison with unconjugated primary on
serial sections of the same TMA. The down-selected conjugate is tested at different concentra-
tions on a TMA with tumor tissue of interest to determine the optimal concentration for stain-
ing. In parallel, a set of TMA serial sections are pre-treated with different rounds of bleaching
and evaluated for bleaching solution’s effect on antigen of interest by comparing the staining
among this set. Antigens with discernible effects are prioritized for staining early in the
sequence, immediately after primary secondary staining of targets which failed to conjugate.
(TIF)
S3 Fig. Marker Staining quality assessment. A: Marker staining performance in each cohort
(True-positive, False-negative), staining round, subcellular location used for analysis and gene
symbol, B: examples of quantitative FOV level correlation of marker intensities on replicate
slides (Pearson correlation coefficients are shown), C: Examples of fluorescence image overlays
of various hallmark markers showing heterogeneity of expression in astrocytoma.
(TIFF)
S4 Fig. Number of segmented cells in serial sections. High correlation in number of seg-
mented cells was observed between serial sections, particularly for the treatment naïve glioma
cohort and two out of three sections of the recurrent GBM cohort. The Pearson correlation
coefficient was computed and is presented in each slide to slide correlation plot.
(TIF)
S5 Fig. Example workflow for calculating cell molecular state and cell spatial heterogene-
ity. Example of how molecular state and cell spatial heterogeneity metrics are calculated, using
EGFR as an example. A. Segmentation of cells using DAPI staining and generation of nuclear
and extra-nuclear masks; B. EGFR fluorescence intensity is quantified for each cell and discre-
tized as low, moderate, and high. The different levels of cell expression are shown as red
(high), green (moderate) or blue (low). C. For each cell (I through v in this cartoon), adjacent
neighboring (touching) cells are counted, and their Spatial State is used to sum the Spatial Het-
erogeneity.
(TIF)
S6 Fig. Uni- (A) and multivariate (B) analysis of biomarker expression and overall survival
as a function of IDH mutation status A. Differences in individual biomarker expression and
survival of IDHmt and IDHwt patients. B. A predictive multivariate model of IDH mutation
status.
(TIFF)
S7 Fig. Lollipop plots for biomarker expression in each cluster, relative to population
median. Protein expression profiles of individual clusters plotted relative to median expression
in the whole population. Solid circles represent the average expression in the cluster while
direction and length of the lollipop shows difference in expression relative to population
median (left-lower, right-higher).
(TIF)
S8 Fig. Cell clusters based on angiogenesis hallmark proteins. Unsupervised clustering of
cells using angiogenesis hallmark proteins identified a 5 cluster set. Clusters with lower than
average hallmark protein expression (1 & 2) are highly represented in samples with IDH1
mutation. Cluster 4 & 5 with higher expression are proportionally more abundant in IDH1wt
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samples.
(TIF)
S9 Fig. Abundance of distinguisher genes (mRNA)/class per patient. A: Relative proportion
of cells belonging to different CellDistinguisher classes in each sample. Class 3 is highly repre-
sented in IDHwt samples. B: shows relative abundance of distinguisher genes grouped by hall-
marks in individual classes.
(TIF)
S10 Fig. Molecular and spatial heterogeneity in grade III gliomas and recurrent GBM
IDHwt and IDHmt tumors. Molecular and spatial heterogeneity in grade III gliomas and
recurrent GBM IDHwt and IDHmt tumors according to the following hallmarks: Invasion
and Motility, Cell Proliferative Signaling and Inducing Angiogenesis. The Mann-Whitney test
was performed on all unpaired comparisons with the resulting p-value presented in each plot.
The p-values were not adjusted for multiple testing.
(TIF)
S11 Fig. Differences in MR features across the population range of RNA and protein
marker expression for angiogenesis. Correlation between Normalized enhancing core vol-
ume (derived from MRI) and Angiogenesis estimated from (a,d) RNA expression levels, and,
based on multiplex immunofluorescence (MxIF) angiogenesis markers (b, e) S100A4 and (c,f)
VEGFR2; (a-c) shows the plots on Cohort 1 (CW Glioma, treatment naive) while (d-f) show
cohort 2 (UCSF, recurrent GBM). A progressive increasing trend may be observed in both
cohorts when examining the normalized enhancing core volume for low, medium and high
angiogenesis. The trends across the enhancement ratio are also conserved when comparing
RNA with MxIF Angiogenesis. None of these comparisons reach statistical significance after
multiple comparison correction using false discovery rate.
(TIF)
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